Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Lynn E Heasley

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSDM-Craniofacial Biology
Phone303/724-4578

    Collapse Research 
    Collapse research activities and funding
    I01BX004751     (HEASLEY, LYNN E)Jul 1, 2019 - Jun 30, 2028
    NIH
    Regulation of Targeted Therapeutic Response by the Immune Microenvironment in HNSCC
    Role: Principal Investigator
    I01BX001994     (HEASLEY, LYNN E)Oct 1, 2013 - Sep 30, 2017
    NIH
    An FGFR1 oncogene driver pathway in head and neck cancer
    Role: Principal Investigator
    R01CA127105     (HEASLEY, LYNN E)Dec 1, 2007 - Nov 30, 2013
    NIH
    FGF-2 Autocrine Signaling in Lung Cancer
    Role: Principal Investigator
    R01CA116527     (HEASLEY, LYNN E)Mar 1, 2007 - Dec 31, 2012
    NIH
    Role of JNK Pathway in Lung Tumorigenesis
    Role: Principal Investigator
    R01GM061718     (HEASLEY, LYNN E)Aug 1, 2001 - Jul 31, 2005
    NIH
    Integrated MAP Kinase Signaling In Cell Differentiation
    Role: Principal Investigator
    R01DK059756     (HEASLEY, LYNN E)Sep 30, 2000 - Aug 31, 2005
    NIH
    MAP KINASES AS MEDIATORS OF DIABETIC NEUROPATHY
    Role: Principal Investigator
    R29GM048826     (HEASLEY, LYNN E)Aug 1, 1993 - Jul 31, 1999
    NIH
    PERSISTENT KINASE SIGNALS IN PC12 CELL DIFFERENTIATION
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Schubert L, Le AT, Hinz TK, Navarro AC, Nelson-Taylor SK, Nemenoff RA, Heasley LE, Doebele RC. A functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes. Biol Open. 2023 08 15; 12(8). PMID: 37470475.
      View in: PubMed
    2. Schubert L, Le AT, Hinz TK, Navarro A, Nelson-Taylor SK, Nemenoff RA, Heasley LE, Doebele RC. A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes. bioRxiv. 2023 Apr 06. PMID: 37066347.
      View in: PubMed
    3. Sisler DJ, Hinz TK, Le AT, Kleczko EK, Nemenoff RA, Heasley LE. Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models. Front Oncol. 2023; 13:1094123. PMID: 36845684.
      View in: PubMed
    4. Kleczko EK, Hinz TK, Nguyen TT, Gurule NJ, Navarro A, Le AT, Johnson AM, Kwak J, Polhac DI, Clambey ET, Weiser-Evans M, Merrick DT, Yang MC, Patil T, Schenk EL, Heasley LE, Nemenoff RA. Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity. NPJ Precis Oncol. 2023 Feb 04; 7(1):15. PMID: 36739466.
      View in: PubMed
    5. Kleczko EK, Le AT, Hinz TK, Nguyen TT, Navarro A, Hu CJ, Selman AM, Clambey ET, Merrick DT, Lu S, Weiser-Evans M, Nemenoff RA, Heasley LE. Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response. Cancer Lett. 2023 03 01; 556:216062. PMID: 36657561.
      View in: PubMed
    6. Kleczko EK, Poczobutt JM, Navarro AC, Laskowski J, Johnson AM, Korpela SP, Gurule NJ, Heasley LE, Hopp K, Weiser-Evans MCM, Gottlin EB, Bushey RT, Campa MJ, Patz EF, Thurman JM, Nemenoff RA. Upregulation of complement proteins in lung cancer cells mediates tumor progression. Front Oncol. 2022; 12:1045690. PMID: 36686777.
      View in: PubMed
    7. Bhatia S, Nguyen D, Darragh LB, Van Court B, Sharma J, Knitz MW, Piper M, Bukkapatnam S, Gadwa J, Bickett TE, Bhuvane S, Corbo S, Wu B, Lee Y, Fujita M, Joshi M, Heasley LE, Ferris RL, Rodriguez O, Albanese C, Kapoor M, Pasquale EB, Karam SD. EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment. Nat Commun. 2022 06 20; 13(1):3535. PMID: 35725568.
      View in: PubMed
    8. Johnson AM, Boland JM, Wrobel J, Klezcko EK, Weiser-Evans M, Hopp K, Heasley L, Clambey ET, Jordan K, Nemenoff RA, Schenk EL. Cancer Cell-Specific Major Histocompatibility Complex II Expression as a Determinant of the Immune Infiltrate Organization and Function in the NSCLC Tumor Microenvironment. J Thorac Oncol. 2021 10; 16(10):1694-1704. PMID: 34048945.
      View in: PubMed
    9. Hinz TK, Kalkur R, Rabinovitch J, Hinkle W, Heasley LE. TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin. Mol Pharmacol. 2021 08; 100(2):144-154. PMID: 34031188.
      View in: PubMed
    10. Gurule NJ, McCoach CE, Hinz TK, Merrick DT, Van Bokhoven A, Kim J, Patil T, Calhoun J, Nemenoff RA, Tan AC, Doebele RC, Heasley LE. A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. NPJ Precis Oncol. 2021 May 17; 5(1):41. PMID: 34001994.
      View in: PubMed
    11. Korpela SP, Hinz TK, Oweida A, Kim J, Calhoun J, Ferris R, Nemenoff RA, Karam SD, Clambey ET, Heasley LE. Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response. J Transl Med. 2021 01 23; 19(1):43. PMID: 33485341.
      View in: PubMed
    12. Neuwelt AJ, Kimball AK, Johnson AM, Arnold BW, Bullock BL, Kaspar RE, Kleczko EK, Kwak JW, Wu MH, Heasley LE, Doebele RC, Li HY, Nemenoff RA, Clambey ET. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. J Immunother Cancer. 2020 04; 8(1). PMID: 32312906.
      View in: PubMed
    13. Johnson AM, Bullock BL, Neuwelt AJ, Poczobutt JM, Kaspar RE, Li HY, Kwak JW, Hopp K, Weiser-Evans MCM, Heasley LE, Schenk EL, Clambey ET, Nemenoff RA. Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma. J Immunol. 2020 04 15; 204(8):2295-2307. PMID: 32179637.
      View in: PubMed
    14. Oweida AJ, Darragh L, Phan A, Binder D, Bhatia S, Mueller A, Court BV, Milner D, Raben D, Woessner R, Heasley L, Nemenoff R, Clambey E, Karam SD. STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer. J Natl Cancer Inst. 2019 12 01; 111(12):1339-1349. PMID: 30863843.
      View in: PubMed
    15. Sandulache VC, Lei YL, Heasley LE, Chang M, Amos CI, Sturgis EM, Graboyes E, Chiao EY, Rogus-Pulia N, Lewis J, Madabhushi A, Frederick MJ, Sabichi A, Ittmann M, Yarbrough WG, Chung CH, Ferrarotto R, Mai W, Skinner HD, Duvvuri U, Gerngross P, Sikora AG. Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting. Oral Oncol. 2020 03; 102:104440. PMID: 31648864.
      View in: PubMed
    16. Hinz TK, Kleczko EK, Singleton KR, Calhoun J, Marek LA, Kim J, Tan AC, Heasley LE. Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. Mol Pharmacol. 2019 12; 96(6):862-870. PMID: 31554698.
      View in: PubMed
    17. Hinz TK, Heasley LE. Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies. Semin Cancer Biol. 2020 04; 61:11-22. PMID: 31546009.
      View in: PubMed
    18. Sisler DJ, Heasley LE. Therapeutic opportunity in innate immune response induction by oncogene-targeted drugs. Future Med Chem. 2019 05; 11(10):1083-1086. PMID: 31084208.
      View in: PubMed
    19. Gibson ES, Woolfrey KM, Li H, Hogan PG, Nemenoff RA, Heasley LE, Dell'Acqua ML. Subcellular Localization and Activity of the Mitogen-Activated Protein Kinase Kinase 7 (MKK7) ? Isoform are Regulated through Binding to the Phosphatase Calcineurin. Mol Pharmacol. 2019 01; 95(1):20-32. PMID: 30404891.
      View in: PubMed
    20. Gurule NJ, Heasley LE. Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses. Cancer Drug Resist. 2018; 1:118-125. PMID: 30656289.
      View in: PubMed
    21. Ng TL, Yu H, Smith DE, Boyle TA, York ER, Leedy S, Gao D, Aisner DL, Van Bokhoven A, Heasley LE, Hirsch FR, Camidge DR. Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. Clin Lung Cancer. 2019 01; 20(1):e39-e51. PMID: 30297175.
      View in: PubMed
    22. Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, Bukkapatnam S, Van Court B, Uyanga N, Darragh L, Kim HM, Raben D, Tan AC, Heasley L, Clambey E, Nemenoff R, Karam SD. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clin Cancer Res. 2018 11 01; 24(21):5368-5380. PMID: 30042205.
      View in: PubMed
    23. Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, Friedman MB, Dwyer-Nield LD, Tennis MA, O'Keefe MC, Donald EJ, Malloy JM, van Bokhoven A, Wilson S, Koch PJ, O'Shea C, Coldren C, Orlicky DJ, Lu X, Baron AE, Hickey G, Kennedy TC, Powell R, Heasley L, Bunn PA, Geraci M, Nemenoff RA. Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res. 2018 09 01; 78(17):4971-4983. PMID: 29997230.
      View in: PubMed
    24. Bhatia S, Griego A, Lennon S, Oweida A, Sharma J, Rohmer C, Uyanga N, Bukkapatnam S, Van Court B, Raben D, Young C, Heasley L, Karam SD. Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor. Mol Cancer Ther. 2018 09; 17(9):2049-2059. PMID: 29970482.
      View in: PubMed
    25. Ren S, Rivard CJ, Yu H, Genova C, Rozenboom L, Gao D, Hinz TK, Rikke BA, Wynes MW, Caldwell C, Agustoni F, Jiang T, Zhou C, Heasley LE, Hirsch FR. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer. 2018 09; 19(5):450-456. PMID: 30146263.
      View in: PubMed
    26. Bhatia S, Sharma J, Bukkapatnam S, Oweida A, Lennon S, Phan A, Milner D, Uyanga N, Jimeno A, Raben D, Somerset H, Heasley L, Karam SD. Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers. Clin Cancer Res. 2018 09 15; 24(18):4539-4550. PMID: 29848571.
      View in: PubMed
    27. Kleczko EK, Heasley LE. Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer. 2018 02 19; 17(1):60. PMID: 29458371.
      View in: PubMed
    28. Pilling AB, Kim J, Estrada-Bernal A, Zhou Q, Le AT, Singleton KR, Heasley LE, Tan AC, DeGregori J, Doebele RC. ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget. 2018 Feb 06; 9(10):8823-8835. PMID: 29507657.
      View in: PubMed
    29. Li HY, McSharry M, Bullock B, Nguyen TT, Kwak J, Poczobutt JM, Sippel TR, Heasley LE, Weiser-Evans MC, Clambey ET, Nemenoff RA. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Cancer Immunol Res. 2017 09; 5(9):767-777. PMID: 28819064.
      View in: PubMed
    30. Oweida A, Lennon S, Calame D, Korpela S, Bhatia S, Sharma J, Graham C, Binder D, Serkova N, Raben D, Heasley L, Clambey E, Nemenoff R, Karam SD. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology. 2017; 6(10):e1356153. PMID: 29123967.
      View in: PubMed
    31. Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar SB, Glogowska MJ, Smith MA, Kako S, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC. EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res. 2017 07 01; 77(13):3551-3563. PMID: 28428274.
      View in: PubMed
    32. Suda K, Rozeboom L, Rivard CJ, Yu H, Ellison K, Melnick MAC, Hinz TK, Chan D, Heasley LE, Politi K, Mitsudomi T, Hirsch FR. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer. 2017 07; 109:1-8. PMID: 28577937.
      View in: PubMed
    33. Ohm AM, Tan AC, Heasley LE, Reyland ME. Co-dependency of PKCd and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer. Oncogene. 2017 07 27; 36(30):4370-4378. PMID: 28368426.
      View in: PubMed
    34. Murakami A, Wang L, Kalhorn S, Schraml P, Rathmell WK, Tan AC, Nemenoff R, Stenmark K, Jiang BH, Reyland ME, Heasley L, Hu CJ. Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. Oncogenesis. 2017 Jan 16; 6(1):e287. PMID: 28092369.
      View in: PubMed
    35. Singleton KR, Earley KT, Heasley LE. Analysis of Drug Resistance Using Kinome-Wide Functional Screens. Methods Mol Biol. 2017; 1636:163-177. PMID: 28730479.
      View in: PubMed
    36. Nakachi I, Helfrich BA, Spillman MA, Mickler EA, Olson CJ, Rice JL, Coldren CD, Heasley LE, Geraci MW, Stearman RS. PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines. Clin Transl Sci. 2016 12; 9(6):293-301. PMID: 27766744.
      View in: PubMed
    37. von M?ssenhausen A, Deng M, Billig H, Queisser A, Vogel W, Kristiansen G, Schr?ck A, Bootz F, G?ke F, Franzen A, Heasley L, Kirfel J, Br?gelmann J, Perner S. Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Target Oncol. 2016 10; 11(5):631-642. PMID: 27053219.
      View in: PubMed
    38. von M?ssenhausen A, Sanders C, Thewes B, Deng M, Queisser A, Vogel W, Kristiansen G, Duensing S, Schr?ck A, Bootz F, Brossart P, Kirfel J, Heasley L, Br?gelmann J, Perner S. MERTK as a novel therapeutic target in head and neck cancer. Oncotarget. 2016 May 31; 7(22):32678-94. PMID: 27081701.
      View in: PubMed
    39. Ryall KA, Kim J, Klauck PJ, Shin J, Yoo M, Ionkina A, Pitts TM, Tentler JJ, Diamond JR, Eckhardt SG, Heasley LE, Kang J, Tan AC. An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. BMC Genomics. 2015; 16 Suppl 12:S2. PMID: 26681397.
      View in: PubMed
    40. Merrick DT, Gao D, Miller YE, Keith RL, Baron AE, Feser W, Kennedy TC, Blatchford PJ, Braudrick S, Hirsch FR, Heasley L, Bunn PA, Franklin WA. Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2016 Jan; 9(1):96-104. PMID: 26542061.
      View in: PubMed
    41. Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. Cancer Res. 2015 Oct 15; 75(20):4398-406. PMID: 26359452.
      View in: PubMed
    42. Ryall KA, Shin J, Yoo M, Hinz TK, Kim J, Kang J, Heasley LE, Tan AC. Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data. Bioinformatics. 2015 Dec 01; 31(23):3799-806. PMID: 26206305.
      View in: PubMed
    43. Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, Dziadziuszko R, Jassem J, Varella-Garcia M, Heasley LE, Kowalewski AA, Ellison K, Chen G, Zhou C, Hirsch FR. Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):1083-90. PMID: 26020126.
      View in: PubMed
    44. G?ke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Maessenhausen A, Lankat-Buttgereit B, G?ke A, Golletz C, Kirsten R, Boehm D, Vogel W, Kleczko EK, Eagles JR, Hirsch FR, Van Bremen T, Bootz F, Schroeck A, Kim J, Tan AC, Jimeno A, Heasley LE, Perner S. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. Clin Cancer Res. 2015 Oct 01; 21(19):4356-64. PMID: 26015511.
      View in: PubMed
    45. Kleczko EK, Kim J, Keysar SB, Heasley LR, Eagles JR, Simon M, Marshall ME, Singleton KR, Jimeno A, Tan AC, Heasley LE. An Inducible TGF-?2-TGF?R Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. PLoS One. 2015; 10(5):e0123600. PMID: 25946135.
      View in: PubMed
    46. Marek LA, Hinz TK, von M?ssenhausen A, Olszewski KA, Kleczko EK, Boehm D, Weiser-Evans MC, Nemenoff RA, Hoffmann H, Warth A, Gozgit JM, Perner S, Heasley LE. Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. Mol Cancer Res. 2014 Oct; 12(10):1460-9. PMID: 24966347.
      View in: PubMed
    47. Sena JA, Wang L, Heasley LE, Hu CJ. Hypoxia regulates alternative splicing of HIF and non-HIF target genes. Mol Cancer Res. 2014 Sep; 12(9):1233-43. PMID: 24850901.
      View in: PubMed
    48. Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics. 2014 Sep 01; 30(17):2393-8. PMID: 24812339.
      View in: PubMed
    49. Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, B?hm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA, Camidge DR, Tan AC, Hirsch FR, Heasley LE. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014 Jun 15; 20(12):3299-309. PMID: 24771645.
      View in: PubMed
    50. Schr?ck A, Bode M, G?ke FJ, Bareiss PM, Schairer R, Wang H, Weichert W, Franzen A, Kirsten R, van Bremen T, Queisser A, Kristiansen G, Heasley L, Bootz F, Lengerke C, Perner S. Expression and role of the embryonic protein SOX2 in head and neck squamous cell carcinoma. Carcinogenesis. 2014 Jul; 35(7):1636-42. PMID: 24743512.
      View in: PubMed
    51. Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One. 2013; 8(12):e82236. PMID: 24349229.
      View in: PubMed
    52. Avasarala S, Bikkavilli RK, Van Scoyk M, Zhang W, Lapite A, Hostetter L, Byers JT, Heasley LE, Sohn JW, Winn RA. Heterotrimeric G-protein, Ga16, is a critical downstream effector of non-canonical Wnt signaling and a potent inhibitor of transformed cell growth in non small cell lung cancer. PLoS One. 2013; 8(10):e76895. PMID: 24204697.
      View in: PubMed
    53. G?ke F, G?ke A, von M?ssenhausen A, Franzen A, Sharma R, Kirsten R, B?hm D, Kristiansen G, Stenzinger A, Wynes M, Hirsch FR, Weichert W, Heasley L, Buettner R, Perner S. Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer. Digestion. 2013; 88(3):172-81. PMID: 24135816.
      View in: PubMed
    54. von M?ssenhausen A, Franzen A, Heasley L, Perner S. FGFR1 as a novel prognostic and predictive biomarker in squamous cell cancers of the lung and the head and neck area. Ann Transl Med. 2013 Oct; 1(3):23. PMID: 25332967.
      View in: PubMed
    55. G?ke F, Bode M, Franzen A, Kirsten R, Goltz D, G?ke A, Sharma R, Boehm D, Vogel W, Wagner P, Lengerke C, Kristiansen G, Kirfel J, Van Bremen T, Bootz F, Heasley LE, Schr?ck A, Perner S. Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Mod Pathol. 2013 Oct; 26(10):1298-306. PMID: 23619603.
      View in: PubMed
    56. Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2013 Mar 25; 2:e39. PMID: 23552882.
      View in: PubMed
    57. Singleton KR, Kim J, Hinz TK, Marek LA, Cas?s-Selves M, Hatheway C, Tan AC, DeGregori J, Heasley LE. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Mol Pharmacol. 2013 Apr; 83(4):882-93. PMID: 23371912.
      View in: PubMed
    58. Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, Lu X, Bar?n AE, Franklin WA, Merrick DT, Jedlicka P, DeRyckere D, Heasley LE, Graham DK. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene. 2013 Jul 18; 32(29):3420-31. PMID: 22890323.
      View in: PubMed
    59. Kono SA, Heasley LE, Doebele RC, Camidge DR. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets. 2012 Feb; 12(2):107-23. PMID: 22165970.
      View in: PubMed
    60. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012 Mar 01; 18(5):1472-82. PMID: 22235099.
      View in: PubMed
    61. Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2011 Aug 01; 17(15):5016-25. PMID: 21673064.
      View in: PubMed
    62. Symonds JM, Ohm AM, Carter CJ, Heasley LE, Boyle TA, Franklin WA, Reyland ME. Protein kinase C d is a downstream effector of oncogenic K-ras in lung tumors. Cancer Res. 2011 Mar 15; 71(6):2087-97. PMID: 21335545.
      View in: PubMed
    63. Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, Helfrich BA, Doebele RC, Heasley LE. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One. 2010 Nov 29; 5(11):e14117. PMID: 21152424.
      View in: PubMed
    64. Chen P, O'Neal JF, Ebelt ND, Cantrell MA, Mitra S, Nasrazadani A, Vandenbroek TL, Heasley LE, Van Den Berg CL. Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model. PLoS One. 2010 May 03; 5(5):e10443. PMID: 20454618.
      View in: PubMed
    65. Tennis MA, Van Scoyk M, Heasley LE, Vandervest K, Weiser-Evans M, Freeman S, Keith RL, Simpson P, Nemenoff RA, Winn RA. Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1. Neoplasia. 2010 Mar; 12(3):244-53. PMID: 20234818.
      View in: PubMed
    66. Kono SA, Marshall ME, Ware KE, Heasley LE. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat. 2009 Aug-Oct; 12(4-5):95-102. PMID: 19501013.
      View in: PubMed
    67. Wang XQ, Li H, Van Putten V, Winn RA, Heasley LE, Nemenoff RA. Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. Mol Biol Cell. 2009 Feb; 20(3):791-800. PMID: 19037103.
      View in: PubMed
    68. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA, Heasley LE. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol. 2009 Jan; 75(1):196-207. PMID: 18849352.
      View in: PubMed
    69. Heasley LE, Winn RA. Analysis of Wnt7a-stimulated JNK activity and cJun phosphorylation in non-small cell lung cancer cells. Methods Mol Biol. 2008; 468:187-96. PMID: 19099255.
      View in: PubMed
    70. Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, Stearman R, Weiser-Evans M, Winn RA, Heasley LE, Nemenoff RA. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol. 2008 Mar; 73(3):709-17. PMID: 18055759.
      View in: PubMed
    71. Bin?truy B, Heasley L, Bost F, Caron L, Aouadi M. Concise review: regulation of embryonic stem cell lineage commitment by mitogen-activated protein kinases. Stem Cells. 2007 May; 25(5):1090-5. PMID: 17218395.
      View in: PubMed
    72. Winn RA, Van Scoyk M, Hammond M, Rodriguez K, Crossno JT, Heasley LE, Nemenoff RA. Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem. 2006 Sep 15; 281(37):26943-50. PMID: 16835228.
      View in: PubMed
    73. Heasley LE, Han SY. JNK regulation of oncogenesis. Mol Cells. 2006 Apr 30; 21(2):167-73. PMID: 16682809.
      View in: PubMed
    74. Amura CR, Marek L, Winn RA, Heasley LE. Inhibited neurogenesis in JNK1-deficient embryonic stem cells. Mol Cell Biol. 2005 Dec; 25(24):10791-802. PMID: 16314504.
      View in: PubMed
    75. Abell AN, Rivera-Perez JA, Cuevas BD, Uhlik MT, Sather S, Johnson NL, Minton SK, Lauder JM, Winter-Vann AM, Nakamura K, Magnuson T, Vaillancourt RR, Heasley LE, Johnson GL. Ablation of MEKK4 kinase activity causes neurulation and skeletal patterning defects in the mouse embryo. Mol Cell Biol. 2005 Oct; 25(20):8948-59. PMID: 16199873.
      View in: PubMed
    76. Winn RA, Marek L, Han SY, Rodriguez K, Rodriguez N, Hammond M, Van Scoyk M, Acosta H, Mirus J, Barry N, Bren-Mattison Y, Van Raay TJ, Nemenoff RA, Heasley LE. Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem. 2005 May 20; 280(20):19625-34. PMID: 15705594.
      View in: PubMed
    77. Takada E, Shimo K, Hata K, Abiake M, Mukai Y, Moriyama M, Heasley L, Mizuguchi J. Interferon-beta-induced activation of c-Jun NH2-terminal kinase mediates apoptosis through up-regulation of CD95 in CH31 B lymphoma cells. Exp Cell Res. 2005 Apr 01; 304(2):518-30. PMID: 15748896.
      View in: PubMed
    78. Marek L, Levresse V, Amura C, Zentrich E, Van Putten V, Nemenoff RA, Heasley LE. Multiple signaling conduits regulate global differentiation-specific gene expression in PC12 cells. J Cell Physiol. 2004 Dec; 201(3):459-69. PMID: 15389548.
      View in: PubMed
    79. Winn RA, Heasley LE. Gamma-catenin expression is reduced or absent in a subset of human non-small cell lung cancers, and its re-expression inhibits cell growth. Chest. 2004 May; 125(5 Suppl):122S-3S. PMID: 15136458.
      View in: PubMed
    80. Heasley LE, Petersen BE. Signalling in stem cells: meeting on signal transduction determining the fate of stem cells. EMBO Rep. 2004 Mar; 5(3):241-4. PMID: 14978509.
      View in: PubMed
    81. Zentrich E, Han SY, Pessoa-Brandao L, Butterfield L, Heasley LE. Collaboration of JNKs and ERKs in nerve growth factor regulation of the neurofilament light chain promoter in PC12 cells. J Biol Chem. 2002 Feb 08; 277(6):4110-8. PMID: 11733514.
      View in: PubMed
    82. Dreskin SC, Thomas GW, Dale SN, Heasley LE. Isoforms of Jun kinase are differentially expressed and activated in human monocyte/macrophage (THP-1) cells. J Immunol. 2001 May 01; 166(9):5646-53. PMID: 11313405.
      View in: PubMed
    83. Heasley LE. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene. 2001 Mar 26; 20(13):1563-9. PMID: 11313903.
      View in: PubMed
    84. Refaat Z, Dessev C, Blaine S, Wick M, Butterfield L, Han SY, Heasley LE, Nemenoff RA. Induction of cytosolic phospholipase A2 by oncogenic Ras is mediated through the JNK and ERK pathways in rat epithelial cells. J Biol Chem. 2001 Jan 12; 276(2):1226-32. PMID: 11042196.
      View in: PubMed
    85. Levresse V, Butterfield L, Zentrich E, Heasley LE. Akt negatively regulates the cJun N-terminal kinase pathway in PC12 cells. J Neurosci Res. 2000 Dec 15; 62(6):799-808. PMID: 11107164.
      View in: PubMed
    86. Schwertfeger KL, Hunter S, Heasley LE, Levresse V, Leon RP, DeGregori J, Anderson SM. Prolactin stimulates activation of c-jun N-terminal kinase (JNK). Mol Endocrinol. 2000 Oct; 14(10):1592-602. PMID: 11043575.
      View in: PubMed
    87. Yang T, Huang Y, Heasley LE, Berl T, Schnermann JB, Briggs JP. MAPK mediation of hypertonicity-stimulated cyclooxygenase-2 expression in renal medullary collecting duct cells. J Biol Chem. 2000 Jul 28; 275(30):23281-6. PMID: 10930430.
      View in: PubMed
    88. Zhang TT, Gealy R, Lu X, Heasley LE, Takimoto K, Levitan ES. TRH regulates Kv1.5 gene expression through a Galphaq-mediated PLC-independent pathway. Mol Cell Endocrinol. 2000 Jul 25; 165(1-2):33-9. PMID: 10940481.
      View in: PubMed
    89. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, Reusch JE. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem. 2000 Apr 14; 275(15):10761-6. PMID: 10753867.
      View in: PubMed
    90. Bunn PA, Soriano A, Johnson G, Heasley L. New therapeutic strategies for lung cancer: biology and molecular biology come of age. Chest. 2000 Apr; 117(4 Suppl 1):163S-168S. PMID: 10777473.
      View in: PubMed
    91. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA, Chou TC. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 1999 Dec 15; 59(24):6178-84. PMID: 10626810.
      View in: PubMed
    92. Butterfield L, Zentrich E, Beekman A, Heasley LE. Stress- and cell type-dependent regulation of transfected c-Jun N-terminal kinase and mitogen-activated protein kinase kinase isoforms. Biochem J. 1999 Mar 15; 338 ( Pt 3):681-6. PMID: 10051439.
      View in: PubMed
    93. Wojtaszek PA, Heasley LE, Berl T. In vivo regulation of MAP kinases in Ratus norvegicus renal papilla by water loading and restriction. J Clin Invest. 1998 Nov 15; 102(10):1874-81. PMID: 9819374.
      View in: PubMed
    94. Beekman A, Helfrich B, Bunn PA, Heasley LE. Expression of catalytically inactive phospholipase Cbeta disrupts phospholipase Cbeta and mitogen-activated protein kinase signaling and inhibits small cell lung cancer growth. Cancer Res. 1998 Mar 01; 58(5):910-3. PMID: 9500449.
      View in: PubMed
    95. Wojtaszek PA, Heasley LE, Siriwardana G, Berl T. Dominant-negative c-Jun NH2-terminal kinase 2 sensitizes renal inner medullary collecting duct cells to hypertonicity-induced lethality independent of organic osmolyte transport. J Biol Chem. 1998 Jan 09; 273(2):800-4. PMID: 9422734.
      View in: PubMed
    96. Li X, Van Putten V, Zarinetchi F, Nicks ME, Thaler S, Heasley LE, Nemenoff RA. Suppression of smooth-muscle alpha-actin expression by platelet-derived growth factor in vascular smooth-muscle cells involves Ras and cytosolic phospholipase A2. Biochem J. 1997 Nov 01; 327 ( Pt 3):709-16. PMID: 9581546.
      View in: PubMed
    97. Higashita R, Li L, Van Putten V, Yamamura Y, Zarinetchi F, Heasley L, Nemenoff RA. Galpha16 mimics vasoconstrictor action to induce smooth muscle alpha-actin in vascular smooth muscle cells through a Jun-NH2-terminal kinase-dependent pathway. J Biol Chem. 1997 Oct 10; 272(41):25845-50. PMID: 9325315.
      View in: PubMed
    98. Heasley LE, Thaler S, Nicks M, Price B, Skorecki K, Nemenoff RA. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J Biol Chem. 1997 Jun 06; 272(23):14501-4. PMID: 9169405.
      View in: PubMed
    99. Butterfield L, Storey B, Maas L, Heasley LE. c-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation. J Biol Chem. 1997 Apr 11; 272(15):10110-6. PMID: 9092556.
      View in: PubMed
    100. Berl T, Siriwardana G, Ao L, Butterfield LM, Heasley LE. Multiple mitogen-activated protein kinases are regulated by hyperosmolality in mouse IMCD cells. Am J Physiol. 1997 Mar; 272(3 Pt 2):F305-11. PMID: 9087672.
      View in: PubMed
    101. Fanger GR, Vaillancourt RR, Heasley LE, Montmayeur JP, Johnson GL, Maue RA. Analysis of mutant platelet-derived growth factor receptors expressed in PC12 cells identifies signals governing sodium channel induction during neuronal differentiation. Mol Cell Biol. 1997 Jan; 17(1):89-99. PMID: 8972189.
      View in: PubMed
    102. Gin?s P, Li X, Brown SE, Nakamura T, Guzelian PS, Heasley LE, Schrier RW, Nemenoff RA. Inhibitory actions of cyclic adenosine monophosphate and pertussis toxin define two distinct epidermal growth factor-regulated pathways leading to activation of mitogen-activated protein kinase in rat hepatocytes. Hepatology. 1996 May; 23(5):1167-73. PMID: 8621150.
      View in: PubMed
    103. Heasley LE, Storey B, Fanger GR, Butterfield L, Zamarripa J, Blumberg D, Maue RA. GTPase-deficient G alpha 16 and G alpha q induce PC12 cell differentiation and persistent activation of cJun NH2-terminal kinases. Mol Cell Biol. 1996 Feb; 16(2):648-56. PMID: 8552093.
      View in: PubMed
    104. Heasley LE, Zamarripa J, Storey B, Helfrich B, Mitchell FM, Bunn PA, Johnson GL. Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase-deficient G alpha 16. J Biol Chem. 1996 Jan 05; 271(1):349-54. PMID: 8550585.
      View in: PubMed
    105. Gin?s P, Li X, Zamarripa JL, Brown SE, Wieder ED, Nakamura T, Guzelian PS, Schrier RW, Heasley LE, Nemenoff RA. Tyrosine kinase growth factor receptors but not seven-membrane-spanning receptors or phorbol esters activate mitogen-activated protein kinase in rat hepatocytes. Hepatology. 1995 Oct; 22(4 Pt 1):1296-303. PMID: 7557884.
      View in: PubMed
    106. Prasad MV, Dermott JM, Heasley LE, Johnson GL, Dhanasekaran N. Activation of Jun kinase/stress-activated protein kinase by GTPase-deficient mutants of G alpha 12 and G alpha 13. J Biol Chem. 1995 Aug 04; 270(31):18655-9. PMID: 7629196.
      View in: PubMed
    107. Wong R, Heasley L, Ao L, Berl T. Expression of GTPase-deficient Ras inhibits vasopressin signaling in cultured cortical collecting duct cells. J Clin Invest. 1995 Jul; 96(1):597-601. PMID: 7615832.
      View in: PubMed
    108. Vaillancourt RR, Heasley LE, Zamarripa J, Storey B, Valius M, Kazlauskas A, Johnson GL. Mitogen-activated protein kinase activation is insufficient for growth factor receptor-mediated PC12 cell differentiation. Mol Cell Biol. 1995 Jul; 15(7):3644-53. PMID: 7540718.
      View in: PubMed
    109. Dhanasekaran N, Heasley LE, Johnson GL. G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev. 1995 Jun; 16(3):259-70. PMID: 7671848.
      View in: PubMed
    110. Mitchell FM, Heasley LE, Qian NX, Zamarripa J, Johnson GL. Differential modulation of bombesin-stimulated phospholipase C beta and mitogen-activated protein kinase activity by [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P. J Biol Chem. 1995 Apr 14; 270(15):8623-8. PMID: 7536738.
      View in: PubMed
    111. Goldman F, Jensen WA, Johnson GL, Heasley L, Cambier JC. gp120 ligation of CD4 induces p56lck activation and TCR desensitization independent of TCR tyrosine phosphorylation. J Immunol. 1994 Oct 01; 153(7):2905-17. PMID: 7522245.
      View in: PubMed
    112. Heasley LE, Senkfor SI, Winitz S, Strasheim A, Teitelbaum I, Berl T. Hormonal regulation of MAP kinase in cultured rat inner medullary collecting tubule cells. Am J Physiol. 1994 Sep; 267(3 Pt 2):F366-73. PMID: 8092250.
      View in: PubMed
    113. Winitz S, Gupta SK, Qian NX, Heasley LE, Nemenoff RA, Johnson GL. Expression of a mutant Gi2 alpha subunit inhibits ATP and thrombin stimulation of cytoplasmic phospholipase A2-mediated arachidonic acid release independent of Ca2+ and mitogen-activated protein kinase regulation. J Biol Chem. 1994 Jan 21; 269(3):1889-95. PMID: 8294438.
      View in: PubMed
    114. Nemenoff RA, Winitz S, Qian NX, Van Putten V, Johnson GL, Heasley LE. Phosphorylation and activation of a high molecular weight form of phospholipase A2 by p42 microtubule-associated protein 2 kinase and protein kinase C. J Biol Chem. 1993 Jan 25; 268(3):1960-4. PMID: 8380583.
      View in: PubMed
    115. Abdel-Hafiz HA, Heasley LE, Kyriakis JM, Avruch J, Kroll DJ, Johnson GL, Hoeffler JP. Activating transcription factor-2 DNA-binding activity is stimulated by phosphorylation catalyzed by p42 and p54 microtubule-associated protein kinases. Mol Endocrinol. 1992 Dec; 6(12):2079-89. PMID: 1337144.
      View in: PubMed
    116. Gallego C, Gupta SK, Heasley LE, Qian NX, Johnson GL. Mitogen-activated protein kinase activation resulting from selective oncogene expression in NIH 3T3 and rat 1a cells. Proc Natl Acad Sci U S A. 1992 Aug 15; 89(16):7355-9. PMID: 1323832.
      View in: PubMed
    117. Heasley LE, Johnson GL. The beta-PDGF receptor induces neuronal differentiation of PC12 cells. Mol Biol Cell. 1992 May; 3(5):545-53. PMID: 1319243.
      View in: PubMed
    118. Gupta SK, Gallego C, Johnson GL, Heasley LE. MAP kinase is constitutively activated in gip2 and src transformed rat 1a fibroblasts. J Biol Chem. 1992 Apr 25; 267(12):7987-90. PMID: 1314814.
      View in: PubMed
    119. Gupta SK, Dhanasekaran N, Heasley LE, Johnson GL. Activating mutations in the NH2- and COOH-terminal moieties of the Gs alpha subunit have dominant phenotypes and distinguishable kinetics of adenylyl cyclase stimulation. J Cell Biochem. 1991 Dec; 47(4):359-68. PMID: 1665495.
      View in: PubMed
    120. Heasley LE, Benedict S, Gleavy J, Johnson GL. Requirement of the adenovirus E1A transformation domain 1 for inhibition of PC12 cell neuronal differentiation. Cell Regul. 1991 Jun; 2(6):479-89. PMID: 1832020.
      View in: PubMed
    121. Wadzinski BE, Heasley LE, Johnson GL. Multiplicity of protein serine-threonine phosphatases in PC12 pheochromocytoma and FTO-2B hepatoma cells. J Biol Chem. 1990 Dec 15; 265(35):21504-8. PMID: 2174876.
      View in: PubMed
    122. Gupta SK, Diez E, Heasley LE, Osawa S, Johnson GL. A G protein mutant that inhibits thrombin and purinergic receptor activation of phospholipase A2. Science. 1990 Aug 10; 249(4969):662-6. PMID: 2166341.
      View in: PubMed
    123. Osawa S, Heasley LE, Dhanasekaran N, Gupta SK, Woon CW, Berlot C, Johnson GL. Mutation of the Gs protein alpha subunit NH2 terminus relieves an attenuator function, resulting in constitutive adenylyl cyclase stimulation. Mol Cell Biol. 1990 Jun; 10(6):2931-40. PMID: 1692962.
      View in: PubMed
    124. Heasley LE, Dhanasekaran N, Gupta SK, Osawa S, Johnson GL. Chimeras of the Gs alpha subunit that had the NH2- or COOH-terminal sequence substituted for the corresponding region of the Gi alpha subunit constitutively activate adenylyl cyclase. Soc Gen Physiol Ser. 1990; 45:117-24. PMID: 2165634.
      View in: PubMed
    125. Woon CW, Heasley L, Osawa S, Johnson GL. Mutation of glycine 49 to valine in the alpha subunit of GS results in the constitutive elevation of cyclic AMP synthesis. Biochemistry. 1989 May 30; 28(11):4547-51. PMID: 2548581.
      View in: PubMed
    126. Heasley LE, Johnson GL. Regulation of protein kinase C by nerve growth factor, epidermal growth factor, and phorbol esters in PC12 pheochromocytoma cells. J Biol Chem. 1989 May 25; 264(15):8646-52. PMID: 2785993.
      View in: PubMed
    127. Woon CW, Soparkar S, Heasley L, Johnson GL. Expression of a G alpha s/G alpha i chimera that constitutively activates cyclic AMP synthesis. J Biol Chem. 1989 Apr 05; 264(10):5687-93. PMID: 2466829.
      View in: PubMed
    128. Heasley LE, Johnson GL. Detection of nerve growth factor and epidermal growth factor-regulated protein kinases in PC12 cells with synthetic peptide substrates. Mol Pharmacol. 1989 Mar; 35(3):331-8. PMID: 2784535.
      View in: PubMed
    129. Weiss ER, Kelleher DJ, Woon CW, Soparkar S, Osawa S, Heasley LE, Johnson GL. Receptor activation of G proteins. FASEB J. 1988 Oct; 2(13):2841-8. PMID: 3139484.
      View in: PubMed
    130. Brunton LL, Heasley LE. cAMP export and its regulation by prostaglandin A1. Methods Enzymol. 1988; 159:83-93. PMID: 2842644.
      View in: PubMed
    131. Heasley LE, Watson MJ, Brunton LL. Putative inhibitor of cyclic AMP efflux: chromatography, amino acid composition, and identification as a prostaglandin A1-glutathione adduct. J Biol Chem. 1985 Sep 25; 260(21):11520-3. PMID: 2995341.
      View in: PubMed
    132. Heasley LE, Brunton LL. Prostaglandin A1 metabolism and inhibition of cyclic AMP extrusion by avian erythrocytes. J Biol Chem. 1985 Sep 25; 260(21):11514-9. PMID: 2995340.
      View in: PubMed
    133. Heasley LE, Azari J, Brunton LL. A glutathione adduct of prostaglandin A1 acts intracellularly to elevate cyclic AMP by inhibiting its extrusion. J Cyclic Nucleotide Protein Phosphor Res. 1985; 10(1):3-8. PMID: 2984263.
      View in: PubMed
    134. Heasley LE, Azari J, Brunton LL. Export of cyclic AMP from avian red cells. Independence from major membrane transporters and specific inhibition by prostaglandin A. Mol Pharmacol. 1985 Jan; 27(1):60-5. PMID: 2981402.
      View in: PubMed
    135. McConnell MR, McAbee DD, Heasley LE, Schoelz JE, Harlow DR, Starn DR. Bacteriophage epsilon 15 is released intact from the surface of its host cell, Salmonella anatum, at Acidic pH. Virology. 1982 Jan 30; 116(2):650-3. PMID: 7064349.
      View in: PubMed
    Heasley's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (634) concept(s)
    _
    Co-Authors Expand Description
    See all (49) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)